ARROW expands presence in Vietnam with DASH support, bringing smart bathroom solutions to local consumers
Leading premium bathroom brand ARROW is expanding its presence in Vietnam, bringing a world-class living experience to local consumers through a strategic partnership with DASH Co., Ltd.
HO CHI MINH, VIETNAM - Media OutReach Newswire - 18 April 2025 - Global smart bathroom solutions provider ARROW has officially entered the Vietnamese market, attracting widespread attention and positive reception from consumers and industry partners alike.
Photo
With over 30 years of innovation and growth, ARROW Home Group has become one of the world's most recognized names in smart sanitary ware and bathroom interiors. The brand's strategic partnership with DASH Co., Ltd. to launch its first official flagship showroom in Vietnam marks a significant milestone in ARROW's global expansion strategy and injects new energy into the country's sanitary ware sector.
This launch reflects DASH's bold commitment to bringing advanced technologies into everyday living spaces, meeting the rising expectations of Vietnamese consumers for modern, intelligent home solutions.
Vietnam's rising demand for smart living
In recent years, Vietnam has emerged as a promising market for high-end sanitary ware, driven by rapid urbanization and economic growth, which are fueling demand for modern, tech-enabled living. Consumers are increasingly seeking innovative, smart, and user-friendly home products to enhance their lifestyles.
Recognizing this shift, ARROW has identified Vietnam as a key market in its global expansion. The brand's entry into the country is both timely and strategic, positioning it to cater to a population that values quality, innovation, and functionality.
ARROW is more than a long-established name in the sanitary ware industry — it's a global powerhouse. With a vast network of over 10,000 retail stores, 10 manufacturing facilities and 08 R&D centers, 1 national industrial design center and a presence in more than 60 countries, ARROW has earned a worldwide reputation for innovation and quality. In Southeast Asia, the brand has contributed to numerous large-scale projects in Bangladesh, Indonesia, Myanmar, and beyond, further cementing its regional influence.
Beyond its global scale, ARROW is widely recognized for its human-centered design philosophy and commitment to creative innovation. The brand's products have earned more than 70 prestigious international awards — including the Red Dot, iF, and IDEA — further reinforcing its leadership in both design and quality.
The ARROW Vietnam Flagship Showroom, located at 218A Thành Thái, District 10, Ho Chi Minh City, marks the brand's first official presence in Vietnam. Established and operated by DASH Co., Ltd., this showroom goes beyond a traditional display space, offering a cutting-edge retail experience. It showcases a diverse range of products, including smart toilets, shower systems, vanity cabinets, and kitchen appliances. Notably, ARROW is a trailblazer in the development of smart sanitary solutions for the elderly, a market segment that remains relatively untapped in Vietnam.
ARROW's core technologies include ergonomically designed toilets that alleviate spinal pressure, along with smart toilets featuring automatic opening/closing, auto-flushing, heated seats, and massage washing functions. The brand's advanced shower systems are built with a durable 4-layer nickel-chrome plating and ceramic cartridges that offer up to 20 years of reliability. Additionally, all premium ceramic products are fired at 1,280°C, ensuring exceptional strength and water resistance.
ARROW's exclusive product lines, including the Heyue Series for the elderly and the Luxury bathroom cabinet collection, offer a diverse range of elegant and highly customizable designs. These collections highlight ARROW's commitment to innovation, specifically tailored to meet the unique habits and preferences of local consumers.
DASH – Bridging ARROW and Vietnamese consumers
DASH Co., Ltd. plays a crucial role in ARROW Vietnam, driving the research and development of products tailored to the local market's needs. As ARROW's strategic partner, DASH is committed to pioneering the distribution of smart sanitary solutions. This partnership not only enables ARROW to quickly and efficiently enter the Vietnamese market but also ensures that consumers have access to premium products at competitive prices.
In the long term, DASH is focused not only on expanding its product offerings but also on building a nationwide showroom network, with a strong emphasis on enhancing customer experience and providing exceptional after-sales services.
'The opening of the ARROW showroom in Vietnam marks a significant milestone in DASH's journey to becoming a leading brand in the import and distribution of smart bathroom solutions,' said Ms. Lê Hoàng Diệu Tâm, Chairwoman of DASH Co., Ltd.
Embodying the spirit of 'Intelligence of Living,' which seeks to offer modern, convenient, and trend-forward interior solutions, the ARROW showroom on Thành Thái Street is designed to provide customers with a shopping experience that blends high-tech innovation with natural elements. Spanning three stories and 1,000 m², the showroom is divided into:
The showroom features model layouts and real-life experience zones, thoughtfully designed to help customers visualize and choose the perfect products for their homes. It also caters to young buyers by offering a wide range of products at various price points and quality levels, supporting them in the journey of building their first home.
Looking ahead, DASH is focused on channeling all resources into building a strong foundation for future expansion into other promising markets across the region, extending beyond Ho Chi Minh City. As it progresses on this growth journey, the brand is steadily cementing its ambition to become a leader in smart sanitary ware, bringing advanced technologies closer to every Vietnamese household.
ARROW Vietnam Flagship Showroom
Address: 218A Thành Thái, Ward 14, District 10, Ho Chi Minh City
Website: shop.arrowhome.vn
Hotline: 19001038
Hashtag: #ARROW
The issuer is solely responsible for the content of this announcement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Undiscovered Gems in Asia for June 2025
As global markets continue to navigate a landscape marked by cooling labor conditions and ongoing trade tensions, small-cap stocks have shown resilience, with indices like the Russell 2000 experiencing notable gains. Against this backdrop, the Asian market presents intriguing opportunities for investors seeking to uncover lesser-known companies that could benefit from regional economic dynamics and potential stimulus measures. Identifying promising stocks often involves looking for companies with strong fundamentals that can thrive despite broader market uncertainties. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Hangzhou Xili Intelligent TechnologyLtd NA 11.73% 9.57% ★★★★★★ Wuxi Xinan Technology NA 11.99% 4.45% ★★★★★★ Hubei Three Gorges Tourism Group 11.24% -15.32% 17.90% ★★★★★★ Shanghai Guangdian Electric Group 0.37% -2.33% -33.49% ★★★★★★ Tohoku Steel NA 5.34% -2.26% ★★★★★★ Zhe Jiang Dayang Biotech Group 29.02% 8.38% -9.33% ★★★★★☆ ShenZhen QiangRui Precision Technology 18.68% 41.36% 14.12% ★★★★★☆ Lee's Pharmaceutical Holdings 13.81% -0.34% -27.47% ★★★★★☆ Hangzhou Zhengqiang 26.03% 2.95% 16.75% ★★★★★☆ Yukiguni Factory 134.59% -5.63% -32.04% ★★★★☆☆ Click here to see the full list of 2608 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★☆☆ Overview: Ningbo Lehui International Engineering Equipment Co., Ltd. operates in the engineering equipment sector and has a market cap of CN¥4.80 billion. Operations: The company generates revenue primarily from its engineering equipment segment. It has a market capitalization of CN¥4.80 billion, reflecting its valuation in the industry. The focus on this specific sector suggests targeted revenue streams aligned with engineering solutions. Ningbo Lehui, a notable player in the machinery sector, has seen its earnings grow by 64.9% over the past year, outpacing industry averages. Despite a volatile share price recently, it remains an attractive prospect as it's trading at 88.8% below estimated fair value. The company's net debt to equity ratio stands at a satisfactory 3.1%, though interest coverage is weak with EBIT covering only 1.8 times interest payments. Recent financials reveal net income of CNY 8.94 million for Q1 2025 and an annual dividend increase to CNY 0.40 per share, reflecting strong profitability and shareholder returns. Take a closer look at Ningbo Lehui International Engineering EquipmentLtd's potential here in our health report. Gain insights into Ningbo Lehui International Engineering EquipmentLtd's past trends and performance with our Past report. Simply Wall St Value Rating: ★★★★☆☆ Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech industry and has a market capitalization of CN¥14.19 billion. Operations: Beijing Zhong Ke San Huan High-Tech generates revenue primarily through its operations in the high-tech sector, with a market capitalization of CN¥14.19 billion. Zhong Ke San Huan, a relatively small player in the tech industry, has shown a mixed financial performance. Over the past year, earnings surged by 64.7%, outpacing the electronic industry's growth of 2.7%. Despite this impressive growth, recent figures reveal challenges; Q1 2025 sales dropped to CNY 1.46 billion from CNY 1.65 billion a year earlier, though net income turned positive at CNY 13.49 million compared to a loss previously reported. The company trades at an attractive valuation—43% below its estimated fair value—and maintains more cash than total debt despite a rising debt-to-equity ratio now at 12.4%. Click to explore a detailed breakdown of our findings in Beijing Zhong Ke San Huan High-Tech's health report. Understand Beijing Zhong Ke San Huan High-Tech's track record by examining our Past report. Simply Wall St Value Rating: ★★★★★★ Overview: Goldsun Building Materials Co., Ltd. operates in the production and sale of premixed concrete, cement, and calcium silicate board across Taiwan and Mainland China, with a market capitalization of approximately NT$53.55 billion. Operations: Goldsun's primary revenue streams are derived from its Taiwan ready-mixed business, generating NT$18.89 billion, and its ready-mixed cement business in Mainland China, contributing NT$1.09 billion. Goldsun Building Materials, a promising player in the industry, has seen its earnings grow by 31.1% over the past year, outpacing the Basic Materials sector's 15.6%. The company's net debt to equity ratio is at a satisfactory 22.3%, reflecting prudent financial management as it decreased from 40.4% over five years. Despite a notable one-off gain of NT$930 million impacting recent results, Goldsun's Price-To-Earnings ratio of 11.6x remains attractive compared to Taiwan's market average of 18.5x. However, future earnings are projected to decline by an average of 16% annually for the next three years, which may temper investor enthusiasm despite recent dividend increases approved for TWD 2.8 per share. Unlock comprehensive insights into our analysis of Goldsun Building Materials stock in this health report. Learn about Goldsun Building Materials' historical performance. Click this link to deep-dive into the 2608 companies within our Asian Undiscovered Gems With Strong Fundamentals screener. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:603076 SZSE:000970 and TWSE:2504. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
6 hours ago
- Business Upturn
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
